| Autor: |
Serafín-López, J., Talavera-Paulin, M., Amador-Molina, J. C., Alvarado-Riverón, M., Vilchis-Landeros, M. M., Méndez-Ortega, P., Fafutis-Morris, M., Paredes-Cervantes, V., López-Santiago, R., León, C. I., Guerrero, M. I., Ribas-Aparicio, R. M., Mendoza-Hernández, G., Carreño-Martínez, C., Estrada-Parra, S., Estrada-García, I. |
| Zdroj: |
Clinical and Vaccine Immunology (formerly CDLI); May 2011, Vol. 18 Issue: 7 p1097-1103, 7p |
| Abstrakt: |
ABSTRACTLeprosy is an infectious disease caused by Mycobacterium leprae, which is a noncultivable bacterium. One of the principal goals of leprosy research is to develop serological tests that will allow identification and early treatment of leprosy patients. M. habanais a cultivable nonpathogenic mycobacterium and candidate vaccine for leprosy, and several antigens that cross-react between M. lepraeand M. habanahave been discovered. The aim of the present study was to extend the identification of cross-reactive antigens by identifying M. habanaproteins that reacted by immunoblotting with antibodies in serum samples from leprosy patients but not with antibodies in sera from tuberculosis (TB) patients or healthy donors (HDs). A 28-kDa antigen that specifically reacted with sera from leprosy patients was identified. To further characterize this antigen, protein spots were aligned in two-dimensional polyacrylamide gels and Western blots. Spots cut out from the gels were then analyzed by mass spectrometry. Two proteins were identified: enoyl-coenzyme A hydratase (lipid metabolism; ML2498) and antigen 85B (Ag85B; mycolyltransferase; ML2028). These proteins represent promising candidates for the design of a reliable tool for the serodiagnosis of lepromatous leprosy, which is the most frequent form in Mexico. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
